Renalytix AI (GB:RENX) has released an update.
Renalytix, an AI-powered diagnostics company, has announced its total issued share capital, which amounts to 165,925,513 Ordinary Shares, with each share granting one vote in company matters. This figure is essential for shareholders to calculate their percentage holdings and determine if they need to disclose changes in their shareholding as per regulatory rules. Additionally, the company highlighted its FDA-authorized kidney health prognostic test, KidneyIntelX, which is used for early-stage chronic kidney disease risk assessment in Type 2 diabetes patients.
For further insights into GB:RENX stock, check out TipRanks’ Stock Analysis page.
